Eplerenone reduced the increase in body weight, improved glucose metabolism, modified the RAAS components and reduced adipocyte size and lipid accumulation in the liver, suggesting that MR antagonists might be candidates to prevent aspects of metabolic disorders under obese conditions. The gene discussed is NR3C2; the disease is metabolic disease.